Education
About Us
Working with TipRanks
Follow Us
Illumina (ILMN)
:ILMN
ILMN Analyst Ratings
Hold
7 Buy
9 Hold
3 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ILMN Stock 12 Month Forecast
Average Price Target
$113.56
▲(16.16% Upside)
| Highest Price Target$185.00 | Average Price Target$113.56 | Lowest Price Target$75.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$103
Hold
5.36%
Upside
Reiterated
08/03/25
Illumina's overall stock score is driven by strong financial management and strategic acquisitions. Despite challenges in revenue growth and regulatory constraints, the company's raised guidance and market positioning in proteomics highlight a positive outlook. Technical indicators and valuation further support a favorable investment case.
Scotiabank
$125
Hold
27.86%
Upside
Reiterated
08/05/25
Stephens
$110
Buy
12.52%
Upside
Assigned
08/04/25
Yuko OkuMorgan Stanley
Not Ranked
Morgan Stanley
$100→$105
Hold
7.41%
Upside
Reiterated
08/04/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (NASDAQ: APLS) and Illumina (NASDAQ: ILMN)We continue to believe ILMN is well positioned to remain the market leader in NGS, supported by its differentiated platform, which enables high- throughput sequencing at lower costs while streamlining workflows. However, the evidence of ILMN’s ability to drive sustained elasticity of demand following the NovaSeq X transition (which brought down sequencing cost by ~3x), especially against the backdrop of softer research customer spending due to weak macro conditions, the evolving competitive landscape, and geopolitical tension, remains to be seen. Meanwhile, key drivers of reaccelerating growth such as a workflow-based pricing paradigm, recent/upcoming workflow improvements, multiomic capabilities all remain in their early innings. As such, we remain on the sidelines pending clarity around these dynamics and maintain our EW rating.
UBS
$98→$110
Hold
12.52%
Upside
Reiterated
08/01/25
Robert W. Baird
$105→$106
Hold
8.43%
Upside
Reiterated
08/01/25
Piper Sandler
$185
Buy
89.24%
Upside
Reiterated
08/01/25
Evercore ISI
$128→$135
Buy
38.09%
Upside
Reiterated
08/01/25
J.P. Morgan
$85→$100
Hold
2.29%
Upside
Reiterated
08/01/25
Stifel Nicolaus
$135
Buy
38.09%
Upside
Reiterated
08/01/25
Barclays
$85→$90
Sell
-7.94%
Downside
Reiterated
08/01/25
Canaccord Genuity
$99→$105
Hold
7.41%
Upside
Reiterated
08/01/25
Leerink Partners
$120
Buy
22.75%
Upside
Reiterated
08/01/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$103
Hold
5.36%
Upside
Reiterated
08/03/25
Illumina's overall stock score is driven by strong financial management and strategic acquisitions. Despite challenges in revenue growth and regulatory constraints, the company's raised guidance and market positioning in proteomics highlight a positive outlook. Technical indicators and valuation further support a favorable investment case.
Scotiabank
$125
Hold
27.86%
Upside
Reiterated
08/05/25
Stephens
$110
Buy
12.52%
Upside
Assigned
08/04/25
Yuko OkuMorgan Stanley
Not Ranked
Morgan Stanley
$100→$105
Hold
7.41%
Upside
Reiterated
08/04/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (NASDAQ: APLS) and Illumina (NASDAQ: ILMN)We continue to believe ILMN is well positioned to remain the market leader in NGS, supported by its differentiated platform, which enables high- throughput sequencing at lower costs while streamlining workflows. However, the evidence of ILMN’s ability to drive sustained elasticity of demand following the NovaSeq X transition (which brought down sequencing cost by ~3x), especially against the backdrop of softer research customer spending due to weak macro conditions, the evolving competitive landscape, and geopolitical tension, remains to be seen. Meanwhile, key drivers of reaccelerating growth such as a workflow-based pricing paradigm, recent/upcoming workflow improvements, multiomic capabilities all remain in their early innings. As such, we remain on the sidelines pending clarity around these dynamics and maintain our EW rating.
UBS
$98→$110
Hold
12.52%
Upside
Reiterated
08/01/25
Robert W. Baird
$105→$106
Hold
8.43%
Upside
Reiterated
08/01/25
Piper Sandler
$185
Buy
89.24%
Upside
Reiterated
08/01/25
Evercore ISI
$128→$135
Buy
38.09%
Upside
Reiterated
08/01/25
J.P. Morgan
$85→$100
Hold
2.29%
Upside
Reiterated
08/01/25
Stifel Nicolaus
$135
Buy
38.09%
Upside
Reiterated
08/01/25
Barclays
$85→$90
Sell
-7.94%
Downside
Reiterated
08/01/25
Canaccord Genuity
$99→$105
Hold
7.41%
Upside
Reiterated
08/01/25
Leerink Partners
$120
Buy
22.75%
Upside
Reiterated
08/01/25
Best Analysts Covering Illumina
1 Month
xxx
Success Rate
19/35 ratings generated profit
Average Return
+1.35%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 54.29% of your transactions generating a profit, with an average return of +1.35% per trade.
3 Months
xxx
Success Rate
17/32 ratings generated profit
Average Return
+2.33%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 53.13% of your transactions generating a profit, with an average return of +2.33% per trade.
1 Year
Success Rate
25/32 ratings generated profit
Average Return
+16.50%
reiterated a buy rating 5 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 78.13% of your transactions generating a profit, with an average return of +16.50% per trade.
2 Years
xxx
Success Rate
21/32 ratings generated profit
Average Return
+36.03%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 65.63% of your transactions generating a profit, with an average return of +36.03% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ILMN Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
18
20
12
8
3
Buy
6
6
6
9
11
Hold
24
26
26
26
20
Sell
10
7
5
6
7
Strong Sell
0
0
0
0
0
total
58
59
49
49
41
Each month's total comprises the sum of three months' worth of ratings.
ILMN Financial Forecast
ILMN Stock Forecast FAQ
What is ILMN’s average 12-month price target, according to analysts?
Based on analyst ratings, Illumina’s 12-month average price target is 113.56.
What is ILMN’s upside potential, based on the analysts’ average price target?
Illumina has 16.16% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ILMN a Buy, Sell or Hold?
Illumina has a consensus rating of Hold which is based on 7 buy ratings, 9 hold ratings and 3 sell ratings.
What is Illumina’s price target?
The average price target for Illumina is 113.56. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $185.00 ,the lowest forecast is $75.00. The average price target represents 16.16% Increase from the current price of $97.76.
The highest analyst price target is $185.00 ,the lowest forecast is $75.00. The average price target represents 16.16% Increase from the current price of $97.76.
What do analysts say about Illumina?
Illumina’s analyst rating consensus is a Hold. This is based on the ratings of 19 Wall Streets Analysts.
How can I buy shares of ILMN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.